BioPharmaTrend.com’s Post

📰 It's that time - the Bits in Bio 'Bio AI Weekly' I wrangle has posted: tinyurl.com/mpdbv3u7 👀 Highlights: Genentech open sources gReLU for AI-enabled DNA Sequence Analysis, Novo Novo Nordisk launches “Golden Ticket Program” to support biotech startups, and data from the 2024 ESMO - European Society for Medical Oncology shows that COVID-19 mRNA vaccines may enhance cancer Immunotherapy efficacy(!!) #bio #ai #bioai #techbio #biotech #pharma #deeptech #science #lifescience #medicine #healthtech #synbio #bioeconomy

The Overlooked Simplicity in Biomarker Discovery I'm all for large omics studies and the utility they have in understanding the mechanism of action, especially in the preclinical setting. But, in the early stages of clinical trials, the heterogeneity (often multiple indications and disease stages) and high costs associated with biomarker mining challenge its budget effectiveness and statistical value. Many of the features in a comprehensive gene assay are not of appropriate prevalence in the population or have enough dynamic range to make it a robust biomarker. Historical successes, such as the identification of PSA for prostate cancer, exemplify the potential of targeted, hypothesis-driven research over complex methodologies. Embracing simplicity could lead to more scientifically and economically efficient discoveries, aligning closely with clinical utility and real-world applicability. #biomarkerdiscovery #biomarkers #clinicaltrials ---- Hi, I'm Josie, a strategic biomarker consultant. I provide advice to therapeutics companies on preclinical and clinical biomarker strategy. Follow me to hear more of this or schedule a call with me for a free intro chat.

#Ariceum is pleased to announce that it will be presenting new #radioligand therapy data at the American Association for Cancer Research (#AACR) Annual Meeting 2024 in San Diego, California, from 5-10 April, 2024.   Join Anika Jäkel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at #Ariceum on 9 April when she will present a poster demonstrating new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research partner, UCB.   We look forward to sharing insights and connecting at #AACR2024. Learn more about the data in the press release in the comments below!   #lifesciences #biotech #radiopharmaceuticals #satoreotide #ATT001 #ATT002

🚀 Exciting News! 🚀 Lepton Pharmaceuticals and TAmiRNA GmbH are taking their partnership to the next level with a brand-new agreement! Together, we're diving deep into epigenetic pathways and unlocking the secrets of microRNA activities. Our goal? To revolutionize immune cell therapy and make it even more effective! 🌟🔬 We're thrilled to be at the forefront of biotechnology innovation, advancing cancer research, and improving cell therapy treatments. This collaboration is a major step towards breakthrough discoveries in genomic medicine and personalized healthcare. Learn more about this groundbreaking collaboration here: https://lnkd.in/dsa2ysbr #Biotechnology #Epigenetics #MicroRNA #ImmuneCellTherapy #CancerResearch #CellTherapy #GenomicMedicine #PersonalizedHealthcare #MedicalInnovation #Pharmaceuticals

Target Validation using Inovotion's CAM model (#4/6)   Target validation is an essential and critical phase of the drug discovery process. It plays a role both before and after lead development.   INOVOTION’s technology allows the in vivo evaluation of the consequences of gene modification on cancer proliferation, the development of metastases, and resistance to Standard-of-Care treatments (chemo-, radio-, and/or immuno-therapies), by comparing wild-type cell strains with their mutated variants, and quantifying tumor size, and metastatic invasion.   INOVOTION has a high degree of expertise in this area, allowing us to work with top academic labs, biotechs, and pharma companies in this early phase of drug discovery.   Contact us so that we can give you further information and discuss your specific project. https://lnkd.in/gWQJncb     #oncology   #preclinical    #drugdiscovery   

Very happy to share that our MAT2A program received the IND approval from the FDA - the approval to start human clinical trials.  MAT2A is a very important synthetic lethality target for cancer with IMHO substantial indication expansion potential. And while IDEAYA is leading in this area, we are happy that the molecule designed using AI that we nominated as preclinical candidate (PCC) a while ago successfully completed IND-enabling studies and was cleared for clinical trials. For us, every completed preclinical story is a big test, testament, and major source of data and experience for the entire AI platform. And the Pharma.AI platform gets better with every PCC and with every clinical study. To date, we nominated 18 preclinical candidates, and with today's approval - 7 are now clinical stage.  Like most of our programs, this MAT2A program is available for a deep diver under CDA and for potential out-licensing. Please check out the reporting by Genetic Engineering & Biotechnology News which broke the news: https://lnkd.in/gWyujy-i #AI #AIdrugdiscovery #drugdiscovery #SyntheticLethality #oncology

A rapid, cost-effective in vitro method for assessing the stability of oligonucleotide duplexes, crucial for the development of oligonucleotide therapeutics targeting orphan diseases and cancer :https://lnkd.in/gp9rsJhk 🔹The method addresses the challenge of oligonucleotide instability, especially RNA, in intracellular and circulation conditions. 🔹The protocol suits various oligonucleotide types (siRNA, miRNA, ASOs) without requiring high-level biosafety clearance. 🔹It aids in selecting ideal modification patterns for in vivo analysis, boosting effective therapeutic development. Work by Shreyas Ganesan Iyer and Andrea Kasinski at Purdue University. Reviewed by Chiara Ambrogio, Wendy Hempstock, and Catherine Hurd. Explore publishing with Bio-protocol at https://lnkd.in/gR3QGYz6. #openaccess #reproducibility #lifesciences #research #biochemistry

📰 Read about #Ariceum’s new findings presented at #AACR2024 on the discovery of novel macrocyclic peptide #radioligands for tumor therapy by mRNA display in Drug Discovery World's (DDW) Summer issue 2024! Ariceum's Head of Translational Biology and Non-Clinical Pharmacology, Anika Jäkel spoke with DDW's, Megan Thomas to discuss the 'truly diverse' agenda at AACR which covered 'many forms of therapeutic approaches, with some revelatory findings about new biomarkers that could lead to a new generation of personalised therapies.' Check out the article here ▶ https://lnkd.in/gtSZijU9 #lifesciences #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide

The first step of our holistic approach happens in the clinic: In the operating room, we begin the meticulous process to ensure the integrity of our samples for our multi-omic-multivariate approach. This is crucial for our novel target identification. At Indivumed Therapeutics, we go beyond single gene analysis. By integrating genomics, transcriptomics, proteomics, and clinical data, we uncover new targets for cancer drugs. Proud to combine cutting-edge methods with our unique tissue resources, rapidly frozen to maintain quality, we collaborate with pharmaceutical partners, creating novel screening-ready target packages for the development of innovative cancer therapeutics with a high medical need. #PrecisionOncology #CancerResearch #DrugDiscovery #MultiOmics #Target

The mRNA-technology received worldwide attention during the COVID-19 pandemic. Meanwhile it is an established method in diagnostics which opens up new possibilities for the fight against cancer and other hereditary diseases.   However, until today the production of cell therapeutics has been manual or only partially automated, resulting in productivity and quality variability as well as extraordinarily high costs.   How can we change this?   The RNAuto project aims to provide a cost-effective, high-volume production of mRNAs, mRNA nanocarriers and mRNA-modified cells. By developing bioprocessing methods and production technologies we want to fully automate the production process of mRNA-based drugs and medicines. Consequently, individual therapies could be made available at an affordable price.   More information in our Annual Report 2022/23 page 22 👉 https://lnkd.in/ehq_6hRX   #makingthedifference | #Fraunhofer